EMA — authorised 27 March 2020
- Marketing authorisation holder: Pfizer Europe MA EEIG
- Status: approved
🇪🇺 Eucrisa in European Union
EMA authorised Eucrisa on 27 March 2020
Marketing authorisations
EMA — authorised 27 March 2020
- Application: EMEA/H/C/004863
- Marketing authorisation holder: Pfizer Europe MA EEIG
- Local brand name: Staquis
- Indication: Staquis is indicated for treatment of mild to moderate atopic dermatitis in adults and paediatric patients from 2 years of age with ? 40% body surface area (BSA) affected.
- Status: withdrawn
Eucrisa in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in European Union
Frequently asked questions
Is Eucrisa approved in European Union?
Yes. EMA authorised it on 27 March 2020; EMA authorised it on 27 March 2020.
Who is the marketing authorisation holder for Eucrisa in European Union?
Pfizer Europe MA EEIG holds the EU marketing authorisation.